| INTRODUCTION
Androgens have long been hypothesized to underlie the development of prostate cancer. However, the association between serum sex steroid hormones and prostate cancer risk remains inconsistent. A meta-analysis of 18 prospective studies reported null associations using study-specific circulating concentrations, 1 albeit limited by the use of blood at a single time-point after midlife that may have missed the etiologically relevant time window, and a potentially diluted effect through inclusion of a variable proportion of indolent prostate cancer cases in the era of prostate-specific antigen (PSA) testing. Later epidemiologic studies also did not support the association between circulating sex steroid hormones and prostate cancer risk, 2-4 although some subgroup analyses reported a positive association of aggressive prostate cancer with total testosterone/sex hormone-binding globulin (SHBG) ratio, 5, 6 and an inverse association with the highest quintile of total estradiol/total testosterone ratio. 7 Despite the paucity of evidence for an association between circulating sex steroid hormones and prostate cancer risk, androgenic alopecia (also commonly known as male pattern baldness) used as a proxy for early-life or cumulative exposure to sex steroid hormones has been reported to be associated with aggressive and fatal prostate cancer. [8] [9] [10] Male pattern baldness is the most common hair loss in men
and affects approximately 50% of Caucasian men by age 50. Bald scalp overexpresses androgen receptor (AR) [11] [12] [13] [14] and has higher levels of dihydrotestosterone (DHT), 15 compared with the non-bald region.
This enhanced androgenic action induces miniaturization of scalp hair follicles and causes progressive hair loss. 16 On the other hand, men born with 5α-reductase type II (5αR2, which intracellularly converts testosterone to DHT) deficiency, 17 or castrated before puberty show complete retention of scalp hair. 18 The former observation has led to the use of finasteride (a 5αR2 inhibitor) in balding treatment, which slows scalp hair loss and promotes new scalp hair growth. 19 Although no study has assessed the direct relationship between chest hair density and prostate cancer risk, associations between chest hair density and circulating sex steroid hormones have been reported.
The development of chest hair parallels the surge of androgens in men during puberty. 20 Denser chest hair has been correlated with higher levels of circulating 3α-androstanediol glucuronide (3α-diol-G; a metabolite of DHT in peripheral tissue) 21 and lower SHBG concentrations. 22 Given the role of androgenic action in these dermatological phenotypes, we investigated clinically assessed balding status and chest hair density in relation to circulating and intraprostatic concentrations of sex steroid hormones in the NCI Prostate Tissue
Study in an attempt to understand the potential biological mechanisms underlying associations between the dermatological phenotypes and prostate cancer risk.
| MATERIALS AND METHODS

| Study population
A detailed description of the Prostate Tissue Study has been reported elsewhere. 23 In brief, 422 patients were enrolled from five hospitals 
| Analytic sample
Of 422 enrolled patients, we included 248 prostate cancer patients for this analysis, after excluding 148 without sex hormones assayed in tissue, 14 without a diagnosis of prostate cancer, one without serum hormones and 11 without any measured dermatological information. | 1575 score (from prostatectomy or biopsy) with adjustment for pre-defined potential confounding variables including age at surgery, study site, race, BMI, education, smoking status, and regular alcohol use. As hormone variables were skewed, natural log transformation was applied to non-missing values, and patients with missing values were dropped from regression models for individual hormone variables.
| Statistical analysis
Missing values of potential confounding variables were included in regression models as a separate category. Subgroup analyses were performed by Gleason score (<7 vs ≥7) and race (European American vs African American).
We also conducted two sensitivity analyses: 1) for intraprostatic sex steroid hormones, we used the mean concentrations of two randomly selected tissue pieces to evaluate the robustness of the main results in general linear models, given the potential variation in measurement errors from the use of a variable number of eligible tissue pieces per subject (median = 4); and 2) we alternatively modeled balding status or three-level chest hair density as the outcome and tertiles of each hormone variable as the exposure using binary and ordinal logistic regression, respectively. To assess trends across tertiles, we assigned the median value of each tertile and modeled this as a continuous variable in logistic regressions.
Two-sided P values <0.05 were considered statistically significant. SAS v9.3 (SAS Institute, Inc., Cary, NC) was used for statistical analyses.
| RESULTS
Of the 248 patients in this analysis, 144 (58%) presented some degree of baldness and 52 (22%) some degree of dense chest hair (Table 1) . Ageadjusted correlation between binary balding status and three-level chest hair density was weak (r = 0.05). Patient characteristics distributed evenly by balding status, while patients with dense chest hair were more likely to be European Americans, have a college degree or higher, and have highgrade prostate cancer. After adjustment for age, differences in these characteristics by chest hair density became minimal (data not tabulated).
Supplemental Table S1 shows Geometric means of hormone variables by balding status are shown in Table 2 . Bald patients were more likely to have higher serum testosterone, DHT, estrone, estradiol, and SHBG, as well as higher intraprostatic testosterone concentrations with full adjustment for potential confounding variables. Stratified analyses by
Gleason score showed that such associations were mainly observed in Gleason score ≥7 prostate cancers, although the multiplicative interaction between balding status and Gleason score for each hormone variable was not statistically significant (Supplemental Table S2 ). Meanwhile, stratified analyses by race demonstrated that only bald European Americans had statistically significantly higher testosterone, DHT, and SHBG in serum, and estrone, estradiol, and androstenedione/estrone ratio in tissue (Supplemental Table S3 ).
However, associations were in the same direction among African Americans, and multiplicative interactions were null between balding status and race for individual hormone variables. Given androgenic sensitivity differs by scalp region, 15 we also presented geometric means by three-level scalp balding category in Supplemental Table S4 , despite limited counts for frontal balding only (n = 20).
Distributions of hormone variables were similar between frontal balding only and vertex plus frontal balding, although the latter group appeared to have higher androstenedione in serum (P = 0.013).
Sensitivity analyses in which tertiles of each hormone variable were modeled as the exposure, as opposed to the outcome, provided mostly consistent results, except that the association for intraprostatic testosterone concentrations became null and an inverse association for intraprostatic androstenedione/estrone ratio was observed (adjusted P trend = 0.042, Supplemental Table S5 ). Increased SHBG appeared to drive the association for testosterone in serum; when we modeled testosterone and SHBG simultaneously, the positive Geometric means of hormone variables by chest hair density provided no evidence of an association (Table 3 ). There was little evidence for effect modification by Gleason score (Supplemental Table S6 ) or race (Supplemental Table S7 ). Compared with the main results for chest hair density, modeling tertiles of each hormone variables as the exposure resulted in similarly null associations (Supplemental Table S5 ).
Sensitivity analyses for intraprostatic sex steroid hormones that used two pieces of randomly selected adjacent normal tissue per subject did not materially alter the results, compared with the main models that used all eligible tissues (data not tabulated).
| DISCUSSION
In this study, serum and intraprostatic sex steroid hormones were 32 Prostatic epithelium and stroma express higher concentrations of 5αR2, 33 as highlighted by an efficient reduction in intraprostatic DHT through finasteride treatment 27 and by its comparable efficacy to dutasteride (a dual inhibitor for 5αR1 and 5αR2) treatment for benign prostatic hyperplasia. 34 Meanwhile, sebaceous glands predominantly express 5αR1, and scalp hair follicles produce higher levels of 5αR2. [35] [36] [37] Both isoenzymes play critical roles in balding development as supported by the superior efficacy of dutasteride versus finasteride in treating baldness. 38, 39 Lastly, 5αR1 is the predominant form expressed in chest skin. 40 However, chest hair follicles have been suggested to be less androgen-dependent, 41 and this is in line with the null association of chest hair density with sex steroid hormones in this analysis, albeit two prior observational studies have reported otherwise. Given the strong parallels in androgen dependency and in agerelated changes between scalp hair follicles and the prostate, we speculated that male pattern baldness might serve as a proxy for intrinsic enhanced androgenic action in androgen-responsive organs.
Such enhanced androgenic action may be partly explained by genetic susceptibility, particularly within the AR signaling pathway. For example, genetic variation in AR gene on the X-chromosome has commonly been associated with male pattern baldness in European descendants. [56] [57] [58] Meanwhile, genes involved in androgen biosynthesis and metabolism, as well as AR have been associated with prostate cancer risk. [59] [60] [61] Despite these shared etiological factors, we did not find robust associations between intraprostatic sex steroid hormones and male pattern baldness, although associations were directionally consistent with our hypothesis. This implies that sex steroid hormone-related factors (eg, AR), rather than the sex steroids hormones themselves, play important roles in organ-specific androgenic actions, and that other overlapping pathways may be involved in associations between these two complex conditions.
Although the directional consistency could be explained by the field effect of hormonal carcinogenesis on histologically normal tissue and/or a product of reverse causation from the adjacent cancerous foci-as supported by significantly elevated levels of testosterone, DHT, and estradiol in normal tissue adjacent to Gleason ≥7 tumor foci versus Gleason <7 foci (Supplemental Table S1 )-we did not find evidence that Gleason score modified the association between intraprostatic sex hormones and balding status (Supplemental Table S3 ).
Strengths of this study include central review by an experienced genitourinary pathologist, nurse-assessed dermatological characteristics, and simultaneous measurement of circulating and intraprostatic sex steroid hormones. Limitations include the fact that both circulating and intraprostatic sex hormones were only measured once and, therefore, intra-individual temporal variations could not be assessed. Meanwhile, male pattern baldness at older age may reflect cumulative exposure to circulating sex steroid hormones as opposed to the single time-point we have assessed in serum and tissue at the age of prostate cancer diagnosis (mean = 60, range = 37-86 years), and this mismatched timewindow of sex hormone exposure may have reduced statistical power. Second, we combined hair-loss patterns because the number of frontal balding only was relatively small. Although we were unable to specify whether observed associations were modified by hair-loss patterns, the misclassification of balding status was minimized.
In conclusion, this study provides evidence that elevated circulating testosterone, DHT, estradiol, and SHBG are associated with balding status in prostate cancer cases. Male balding serves as a proxy for circulating sex hormone concentrations and may explain prior studies showing an association between male pattern baldness and prostate cancer incidence and specific mortality. Testosterone is the only elevated intraprostatic sex hormone in men with balding; lack of an association between balding and other intraprostatic sex hormones reaffirms differences in organ-specific sex steroid hormone metabolism and cellular response.
